



Open-Lahel Multicenter Single Ascending Dose Study to Assess the Safety of D-RCMA-101 in Subjects with

Relapsed/Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME)
Alpha Trial Link:
https://clinicaltrials.gov/ct2/show/NCTo3288493
Alpha Clinic (primary): UCSF
Contact:
Name:
James Aguila
Phone:
415-502-8075
Email:
James.Aguila@ucsf.edu
Alpha Trial Sponsor:
Poseida Therapeutics, Inc.
Disease Indication:
Multiple Myeloma
Enrollment Status:
Recruiting

Source URL: https://www.cirm.ca.gov/alphaclinictrial/open-label-multicenter-single-ascending-dose-study-assess-safety-p-bcma-101